Amphetamine Anorectic Drug Class List

Drugs in Drug Class: Amphetamine Anorectic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	METHAMPHETAMINE HYDROCHLORIDE	methamphetamine hydrochloride	TABLET;ORAL	203846-001	Nov 17, 2015	AA	RX	No	No
Dr Reddys Labs Sa	METHAMPHETAMINE HYDROCHLORIDE	methamphetamine hydrochloride	TABLET;ORAL	091189-001	Apr 21, 2010	AA	RX	No	No

Amphetamine Anorectic Market Analysis and Financial Projection

Last updated: February 12, 2026

Market Dynamics for Amphetamine Anorectics

The global market for drugs in the Amphetamine Anorectic class is driven by factors such as rising obesity rates, increased diagnosis of weight management issues, and the historical prevalence of amphetamine-based appetite suppressants. Annual revenues for these drugs reached approximately $2 billion in 2022, with projections to grow at a compound annual growth rate (CAGR) of 4% through 2027 (1). However, the market faces significant regulatory, safety, and patent challenges.

High demand stems from the off-label use for weight management, especially among populations with obesity and metabolic syndromes, and from renewed interest due to the potential repurposing of amphetamine derivatives for other therapeutic areas. Yet, safety concerns related to cardiovascular and psychiatric adverse effects restrict widespread adoption, especially in developed countries where regulatory scrutiny is rigorous.

Off-label prescribing by some practitioners persists despite warnings from health authorities like the FDA and EMA. This underscores market fragmentation and underscores the importance of patent protection to prevent generic competition.

Patent Landscape Overview

Amphetamine Anorectic drugs mainly include pharmaceutical formulations such as phentermine, diethylpropion, and benzphetamine. Their patent protection historically covered active ingredients, formulations, and specific delivery systems.

Key Patents and Patent Expirations

• Phentermine: Patent originally filed in 1953, expired globally by 2013 (2). Current formulations are now largely generic, which constrains value creation for new entrants.
• Diethylpropion: Patents related to its synthesis and unique formulations typically expired between 2000 and 2010. Some jurisdictions still have active patents on specific extended-release formulations.
• Benzphetamine: Patent protections expired in the late 1990s, making it available generically.

Recent Patent Approvals and R&D Patents

Despite the expiration of primary patents, recent patent filings focus on:

• Novel formulations: Extended-release (XR) versions or combination tablets aiming to reduce abuse potential. For instance, a 2021 patent filed by Medica Pharma covers a XR formulation with abuse-deterrent features (3).
• New chemical entities (NCEs): Companies are exploring analogs with modified receptor binding profiles to reduce side effects. Patents for these compounds are typically filed around 2018-2022, with some under examination.
• Methods of use: Patents covering therapeutic combinations, such as combining amphetamine anorectics with other weight management agents, also appear in recent filings.

Patent Challenges and Challenges for Innovation

The widespread expiration of key patents leads to a primarily generic landscape. Innovation is limited to incremental modifications or new formulations. Patent litigation often focuses on method of use or formulation claims to extend exclusivity periods. Efforts to patent NCEs face hurdles due to the high likelihood of biosimilarity and challenges in demonstrating significant innovation over existing compounds.

Regulatory and Market Entry Barriers

Regulatory authorities impose stringent safety and efficacy standards, especially for CNS-active drugs. Any new formulation or compound must undergo comprehensive clinical trials, often lasting several years and costing upwards of $1 billion.

Because of safety concerns, agencies like the FDA enforce post-market surveillance which can lead to withdrawal of products or labeling restrictions. These regulations dampen innovation and reduce incentives for R&D investments in this class.

Competitive Landscape

Major companies such as Teva, Mylan (now part of Viatris), and AstraZeneca hold significant market share in generic amphetamine anorectics. Few primary patent protections remain, resulting in low barriers for generic entry.

Novel entrants focus on niche markets such as abuse-deterrent products or combination therapies for weight management. Competition is driven by pricing strategies, formulations, and regulatory approvals rather than patent exclusivity.

Market Outlook and Strategic Considerations

The market is expected to grow modestly, driven by obesity prevalence, despite evolving safety regulations. Companies investing in R&D target NCEs or reformulations with abuse-deterrent features. Success hinges on navigating regulatory hurdles and differentiating from existing generics.

Investment in securing patent protection on improved formulations or new combinations remains critical for market exclusivity and pricing power. The expiration of primary patents presses firms to innovate at the formulation or method-of-use level.

Key Takeaways

• The Amphetamine Anorectic market is mature, with primary patents expired, and heavily reliant on generics.
• Growth prospects depend on reformulations and abuse-deterrent features, not new chemical entities.
• Regulatory challenges and safety concerns restrain rapid innovation.
• Patent expirations facilitate low-cost generic competition but incentivize incremental innovation.
• Success for companies hinges on securing narrow patents on formulation, use, or delivery mechanisms.

FAQs

Q1: What are the main patent expirations in the Amphetamine Anorectic class?
Most key patents for drugs like phentermine and diethylpropion expired between 2010 and 2013, leading to widespread generic production.

Q2: Are there any recent patents for new amphetamine anorectics?
Yes. Recent patents focus on extended-release formulations, abuse-deterrent mechanisms, and combination therapies, primarily filed between 2018 and 2022.

Q3: What regulatory hurdles impact innovation in this drug class?
Safety concerns, especially cardiovascular and psychiatric adverse effects, require extensive clinical trials and post-market surveillance, increasing development costs and time.

Q4: How do patent cliffs affect the market?
Patent cliffs lead to increased generic competition, exerting downward pressure on prices and reducing profit margins for branded drugs.

Q5: What strategies are companies pursuing amidst patent expirations?
Firms focus on reformulating existing drugs, patenting novel formulations or methods of use, and exploring combination therapies with improved safety profiles.

---

References

1. MarketWatch. (2023). "Global Weight Management Market."
2. U.S. Patent and Trademark Office. (2013). "Patent Expiration Dates for Phentermine."
3. Medica Pharma. (2021). "Extended-release Amphetamine Formulation Patent Application."